Claudia Garimberti -

An update for the increase of prices of medicinal products reimbursed by the Italian NHS has recently been provided by AIFA.


Conditions for the price increase are the following:

  • Documented increase in the manufacturing cost, with particular reference to the cost of the raw material.
  • Documented increase in manufacturing costs due to regulatory provisions concerning the improvement of the quality and safety profile of the specific drug.


Companies will be asked to provide supporting evidence referring to the last 5 years.


Regulatory Pharma Net is available to support Pharmaceutical Companies during the whole product lifecycle with any kind of Pricing and Reimbursement procedure, from the initial P&R application to any renegotiation procedure.


Comments are closed for this post.